Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Beyond converting to telehealth platforms and limiting in-office visits, the Best Practices Committee of the NCCN shares essential approaches to help mitigate the transmission of COVID-19 among patients with cancer and the health care workers who treat them.

This study in Cancer suggests the possibility, pointing to qualitative results of clinical trial principal investigators, research staff, referring clinicians, and cancer center leaders regarding their attitudes and experiences with enrolling minority patients in cancer clinical trials.

Although timely access to the results of studies evaluating patients with cancer infected with COVID-19 is urgently needed, such evidence is currently very limited. The CCC19 hopes to change all of that.

According to a recent study published in Journal of Infectious Diseases, an analysis of four different coronaviruses (OC43, 229E, HKU1 and NL63) over an 8-year period demonstrated that they were detected in a limited timeframe, from December to April and May, with a peak during January and February.

Although no proven therapies exist, this JAMA article explores potential treatments for COVID-19 in repurposed drugs (chloroquine and hydroxychloroquine), lopinavir/ritonavir and other antiretrovirals, investigational drugs such as remdesivir, adjunctive therapies, and others.